Kennedy Capital Management LLC Sells 40,868 Shares of Harrow, Inc. (NASDAQ:HROW)

Kennedy Capital Management LLC decreased its stake in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) by 39.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 63,395 shares of the company's stock after selling 40,868 shares during the period. Kennedy Capital Management LLC owned approximately 0.18% of Harrow worth $2,127,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. AlphaQuest LLC grew its holdings in shares of Harrow by 452.8% during the 4th quarter. AlphaQuest LLC now owns 3,527 shares of the company's stock worth $118,000 after acquiring an additional 2,889 shares during the period. Federated Hermes Inc. purchased a new stake in Harrow in the fourth quarter worth $214,000. Maridea Wealth Management LLC purchased a new stake in Harrow in the fourth quarter worth $222,000. KLP Kapitalforvaltning AS bought a new position in Harrow in the fourth quarter worth $235,000. Finally, China Universal Asset Management Co. Ltd. lifted its position in Harrow by 10.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,552 shares of the company's stock valued at $253,000 after buying an additional 727 shares during the period. Hedge funds and other institutional investors own 72.76% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on HROW shares. HC Wainwright reaffirmed a "buy" rating and set a $57.00 price objective on shares of Harrow in a research report on Monday, March 31st. B. Riley cut their price objective on shares of Harrow from $69.00 to $65.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st.

Harrow Price Performance

Shares of Harrow stock traded up $0.64 during trading hours on Friday, hitting $23.99. The company's stock had a trading volume of 199,238 shares, compared to its average volume of 507,907. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55. Harrow, Inc. has a 12-month low of $9.86 and a 12-month high of $59.23. The business has a 50 day moving average price of $26.12 and a two-hundred day moving average price of $35.70. The company has a market cap of $855.34 million, a PE ratio of -25.52 and a beta of 0.46.

Harrow (NASDAQ:HROW - Get Free Report) last announced its quarterly earnings data on Thursday, March 27th. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.11 by $0.14. Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. The business had revenue of $66.83 million during the quarter, compared to analyst estimates of $66.01 million. Analysts expect that Harrow, Inc. will post -0.53 earnings per share for the current fiscal year.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.